Merck to acquire an Ireland vaccine facility from WuXi Biologics for $500m.

Synopsis

Merck, a global pharmaceutical and chemicals company, agreed to acquire an Ireland vaccine facility from WuXi Biologics, a global open-access biologics technology platform, for $500m.

Principals

target

Wuxi Biologics (ireland Vaccine Facility)

bidder

Merck Kgaa

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy